Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
TO THE EDITOR:Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive large B-cell lymphoma (LBCL) of thymic origin occurring predominantly in young patients and accounting for 2% to 4% of non-Hodgkin lymphomas.1,2 Anti-CD19 chimeric antigen receptor T cells (CARTs) have been adopted as standar...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
October 13, 2023
|
| In: |
Blood advances
Year: 2023, Jahrgang: 7, Heft: 20, Pages: 6191-6195 |
| ISSN: | 2473-9537 |
| DOI: | 10.1182/bloodadvances.2023011203 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/bloodadvances.2023011203
|
| Verfasserangaben: | Maria-Luisa Schubert, Wolfgang A. Bethge, Francis A. Ayuk, Malte von Bonin, Vladan Vucinic, Eva Marie Wagner-Drouet, Marion Subklewe, Claudia D. Baldus, Bertram Glass, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S. Topp, Gerald Wulf, Nicolaus Kröger, Peter Dreger, on behalf of the German Lymphoma Alliance and the German Registry for Stem Cell Transplantation |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1879640783 | ||
| 003 | DE-627 | ||
| 005 | 20240307024934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240131s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023011203 |2 doi | |
| 035 | |a (DE-627)1879640783 | ||
| 035 | |a (DE-599)KXP1879640783 | ||
| 035 | |a (OCoLC)1425207233 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schubert, Maria-Luisa |d 1982- |e VerfasserIn |0 (DE-588)1147867631 |0 (DE-627)1007273801 |0 (DE-576)49608089X |4 aut | |
| 245 | 1 | 0 | |a Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL |b a GLA/DRST registry study |c Maria-Luisa Schubert, Wolfgang A. Bethge, Francis A. Ayuk, Malte von Bonin, Vladan Vucinic, Eva Marie Wagner-Drouet, Marion Subklewe, Claudia D. Baldus, Bertram Glass, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S. Topp, Gerald Wulf, Nicolaus Kröger, Peter Dreger, on behalf of the German Lymphoma Alliance and the German Registry for Stem Cell Transplantation |
| 264 | 1 | |c October 13, 2023 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.01.2024 | ||
| 520 | |a TO THE EDITOR:Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive large B-cell lymphoma (LBCL) of thymic origin occurring predominantly in young patients and accounting for 2% to 4% of non-Hodgkin lymphomas.1,2 Anti-CD19 chimeric antigen receptor T cells (CARTs) have been adopted as standard of care for the treatment of patients with relapsed and/or refractory (r/r) LBCL, including PMBCL beyond second treatment line.3,4 Axicabtagene ciloleucel (axi-cel) has been the first CART therapy specifically approved for treatment of PMBCL in this setting. However, because of the rarity of the disease, information on safety and efficacy of CARTs in PMBCL is limited.5-7 Here, we compared course and outcome of axi-cel-treatment in patients with r/r PMBCL and those with r/r diffuse LBCL (DLBCL), not otherwise specified. | ||
| 700 | 1 | |a Bethge, Wolfgang A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ayuk, Francis A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Bonin, Malte |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vucinic, Vladan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wagner-Drouet, Eva Marie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Subklewe, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Baldus, Claudia D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glass, Bertram |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marks, Reinhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mougiakakos, Dimitrios |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schroers, Roland |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stelljes, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Topp, Max S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wulf, Gerald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kröger, Nicolaus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d Washington, DC : American Society of Hematology, 2016 |g 7(2023), 20 vom: Okt., Seite 6191-6195 |h Online-Ressource |w (DE-627)873588312 |w (DE-600)2876449-3 |w (DE-576)48043249X |x 2473-9537 |7 nnas |a Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL a GLA/DRST registry study |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:20 |g month:10 |g pages:6191-6195 |g extent:5 |a Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL a GLA/DRST registry study |
| 856 | 4 | 0 | |u https://doi.org/10.1182/bloodadvances.2023011203 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240131 | ||
| 993 | |a Editorial | ||
| 994 | |a 2023 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 17 |y j | ||
| 998 | |g 1147867631 |a Schubert, Maria-Luisa |m 1147867631:Schubert, Maria-Luisa |d 910000 |d 910100 |e 910000PS1147867631 |e 910100PS1147867631 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1879640783 |e 4472706628 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL","title":"Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL","subtitle":"a GLA/DRST registry study"}],"note":["Gesehen am 31.01.2024"],"relHost":[{"name":{"displayForm":["American Society of Hematology"]},"disp":"Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL a GLA/DRST registry studyBlood advances","id":{"eki":["873588312"],"issn":["2473-9537"],"zdb":["2876449-3"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 27.04.21"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"American Society of Hematology","dateIssuedDisp":"[2016]-","publisherPlace":"Washington, DC"}],"recId":"873588312","title":[{"title_sort":"Blood advances","title":"Blood advances"}],"language":["eng"],"part":{"extent":"5","pages":"6191-6195","issue":"20","year":"2023","text":"7(2023), 20 vom: Okt., Seite 6191-6195","volume":"7"},"pubHistory":["Vol. 1, iss. 1 (November 2016)-"]}],"id":{"doi":["10.1182/bloodadvances.2023011203"],"eki":["1879640783"]},"physDesc":[{"extent":"5 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1879640783","origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"October 13, 2023"}],"person":[{"family":"Schubert","role":"aut","given":"Maria-Luisa","display":"Schubert, Maria-Luisa"},{"given":"Wolfgang A.","role":"aut","display":"Bethge, Wolfgang A.","family":"Bethge"},{"given":"Francis A.","role":"aut","display":"Ayuk, Francis A.","family":"Ayuk"},{"family":"von Bonin","role":"aut","given":"Malte","display":"von Bonin, Malte"},{"family":"Vucinic","display":"Vucinic, Vladan","role":"aut","given":"Vladan"},{"family":"Wagner-Drouet","role":"aut","given":"Eva Marie","display":"Wagner-Drouet, Eva Marie"},{"given":"Marion","role":"aut","display":"Subklewe, Marion","family":"Subklewe"},{"display":"Baldus, Claudia D.","role":"aut","given":"Claudia D.","family":"Baldus"},{"given":"Bertram","role":"aut","display":"Glass, Bertram","family":"Glass"},{"family":"Marks","display":"Marks, Reinhard","role":"aut","given":"Reinhard"},{"display":"Mougiakakos, Dimitrios","role":"aut","given":"Dimitrios","family":"Mougiakakos"},{"family":"Schroers","display":"Schroers, Roland","role":"aut","given":"Roland"},{"family":"Stelljes","role":"aut","given":"Matthias","display":"Stelljes, Matthias"},{"display":"Topp, Max S.","role":"aut","given":"Max S.","family":"Topp"},{"display":"Wulf, Gerald","given":"Gerald","role":"aut","family":"Wulf"},{"role":"aut","given":"Nicolaus","display":"Kröger, Nicolaus","family":"Kröger"},{"family":"Dreger","display":"Dreger, Peter","given":"Peter","role":"aut"}],"name":{"displayForm":["Maria-Luisa Schubert, Wolfgang A. Bethge, Francis A. Ayuk, Malte von Bonin, Vladan Vucinic, Eva Marie Wagner-Drouet, Marion Subklewe, Claudia D. Baldus, Bertram Glass, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S. Topp, Gerald Wulf, Nicolaus Kröger, Peter Dreger, on behalf of the German Lymphoma Alliance and the German Registry for Stem Cell Transplantation"]}} | ||
| SRT | |a SCHUBERTMAOUTCOMESOF1320 | ||